A study by UK researchers has found that buying patterns for over-the-counter (OTC) medicines for pain and indigestion, recorded using a store loyalty card, could be used to pick up early s
Following the European Society of Gynaecological Oncology (ESGO) 2022 congress, pharmaphorum spoke with experts from among the Ovarian Cancer Commitment (OCC) founding partners – ESGO, the
GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patient
Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas and GISTs) at the Centre Léon Bérard (CLB), a hospital 100%
Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported a phase 3 trial of its lead gene therapy VB-111 for ovarian cancer failed a p